Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 2/20 | 0.32 |
| ▸ | MMP7 | P09237 | 2/20 | 0.32 |
| ▸ | MMP10 | P09238 | 2/20 | 0.32 |
| ▸ | MMP12 | P39900 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6244771 | 0.91 | ALDH1A1 (0.37) | KDM4EALDH1A1MAOAL3MBTL1 | |
| SCHEMBL6499078 | 0.89 | HDAC6 (0.36) | ALDH1A1HDAC6MMP3MMP7AAK1 | |
| SCHEMBL6492451 | 0.84 | ALDH1A1 (0.38) | KDM4EALDH1A1MAOAAAK1 | |
| SCHEMBL6243680 | 0.80 | APEX1 (0.37) | ALDH1A1 | |
| SCHEMBL6337953 | 0.76 | BCHE (0.42) | KDM4EALDH1A1 | |
| SCHEMBL6500489 | 0.70 | SCN10A (0.34) | ALDH1A1HDAC6MMP3MMP7AAK1 | |
| SCHEMBL6500557 | 0.70 | HCAR3 (0.38) | MMP3MMP7 | |
| SCHEMBL6498866 | 0.69 | HCAR3 (0.33) | MMP3MMP7 | |
| SCHEMBL6246043 | 0.69 | SLC6A2 (0.40) | KDM4EAAK1 | |
| SCHEMBL6247442 | 0.68 | SCN10A (0.41) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919331-B2 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1461035-A4 | SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1461035-A2 | SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | Bristol-Myers Squibb Company (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-06 | — | — | US | disclosed |
| WO-2003053344-A2 | SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | KDM4E 335/4885ALDH1A1 3132/4885HDAC6 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.